None listed
Conditions
Interventions
None listed
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Subjects aged 50 years or older. 2.Patients who have visited the Department of Neurology and have been diagnosed with subjective cognitive decline (SCD), mild cognitive impairment (MCI), or early-stage dementia (Clinical Dementia Rating [CDR] = 1). 3.Patients who have visited the Department of Otolaryngology and have moderate-to-severe hearing loss, but are capable of undergoing cognitive assessment with the assistance of hearing aids. 4.Patients with no contraindications to brain magnetic resonance imaging (MRI) or positron emission tomography (PET). 5.Patients who are able and willing to participate in follow-up assessments throughout the 2-year study period.
Exclusion criteria
Exclusion criteria: 1.Subjects with clinically significant findings that, in the opinion of the Principal Investigator or Sub-Investigator, make MRI examination inappropriate. 2.Subjects with medical conditions that preclude MRI or PET imaging (e.g., claustrophobia). 3.Subjects who are expected to be lost to follow-up within the 2-year study period. 4.Subjects who, in the judgment of the investigator, are not suitable for participation in this clinical study or whose participation may increase the risk associated with the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive function scores obtained from standardized neuropsychological assessments. Neuroimaging-based markers of neurodegenerative and vascular brain changes. Brain Amyloid Plaque Load (BAPL) scores derived from amyloid positron emission tomography (PET).;Sensitivity analyses will be performed incorporating amyloid and vascular biomarkers to assess the independent contribution of each factor to the association among hearing function, brain network alterations, and cognitive outcomes.;The effects of hearing aid use will be assessed through longitudinal analyses of changes in brain network topology over the follow-up period. Network measures, including global efficiency, characteristic path length, clustering coefficient, modularity, and transitivity, will be compared to evaluate alterations in the hierarchical organization and efficiency of brain networks. | — |
Countries
Korea, Republic of
Contacts
Public ContactYe Seul Kim
Asan Medical Center
Outcome results
None listed